Publications by authors named "Juin Park"
Trastuzumab is used to treat HER2-amplified metastatic gastric cancer; however, most patients become trastuzumab-resistant within a year. Knowledge of the mechanisms underlying trastuzumab resistance is required to overcome this limitation. Here, we aimed to elucidate this resistance mechanism using four trastuzumab-resistant (TR) cell lines and investigate the efficacy of HER2-targeted therapies to overcome treatment resistance.
View Article and Find Full Text PDFArticle Synopsis
- Trastuzumab, ramucirumab, and paclitaxel were assessed as a second-line treatment for HER2-positive advanced gastric or gastroesophageal junction (G/GEJ) cancer after failure of first-line trastuzumab therapy.
- In a study involving 50 patients, the combination yielded a median progression-free survival of 7.1 months and an overall survival of 13.6 months, with a significant objective response rate of 54%.
- The safety profile of the treatment was manageable, with no major dose-limiting toxicities noted and loss of HER2 expression seen in 34.8% of patients post-first-line treatment, but without a clear link to treatment outcomes.
Purpose: Epigenetic dysregulation is a common characteristic of cancers, including gastric cancer (GC), and contributes to cancer development and progression. Although the efficacy of BET (an epigenetic regulator) inhibition has been demonstrated in various cancer types, predictive genetic markers of its efficacy in GC are currently lacking. Therefore, we aimed to identify markers that predict the response of BET inhibition in GC and, suggest an effective treatment regimen through combined therapy.
View Article and Find Full Text PDF